Company Update (NASDAQ:SGMO): Sangamo Biosciences Inc. Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug application (IND) for its SB-525 gene therapy program for the treatment of ¬†hemophilia A. The IND is now active and enables clinical development to assess the safety, tolerability and potential efficacy of SB-525 in adults with hemophilia A.

“We are very pleased to begin 2017 with the announcement of an open IND for our SB-525 cDNA gene therapy and intend to initiate a clinical trial evaluating SB-525 as soon as possible,” said Sandy Macrae, M.B., Ch.B., Ph.D., CEO of Sangamo. “We are committed to developing the best therapeutic options for patients, and based on non-human primate studies, SB-525 has demonstrated the potential to be the best-in-class treatment for Hemophilia A.”

SB-525 is one of four lead development programs for which Sangamo is planning to conduct clinical trials in 2017. Sangamo is evaluating SB-FIX, an in vivo genome editing therapy for hemophilia B, in a Phase 1/2 clinical trial, with sites currently screening patients for the study. This year Sangamo will also conduct two Phase 1/2 clinical trials evaluating in vivo genome editing therapies for lysosomal storage disorders MPS I (SB-318) and MPS II (SB-913). (Original Source)

Shares of Sangamo Biosciences closed yesterday at $3.50. SGMO has a 1-year high of $8.13 and a 1-year low of $2.65. The stock’s 50-day moving average is $3.30 and its 200-day moving average is $4.44.

On the ratings front, Sangamo Biosciences has been the subject of a number of recent research reports. In a report issued on November 1, Wedbush analyst Liana Moussatos downgraded SGMO to Hold, with a price target of $4, which represents a potential upside of 14% from where the stock is currently trading. Separately, on October 27, Cowen’s Ritu Baral reiterated a Buy rating on the stock.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Liana Moussatos and Ritu Baral have a yearly average return of 8.1% and 3.3% respectively. Moussatos has a success rate of 40% and is ranked #406 out of 4369 analysts, while Baral has a success rate of 38% and is ranked #1037.

Overall, 2 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $4.00 which is 14.3% above where the stock closed yesterday.

Sangamo BioSciences, Inc. researches and develops transcription factors in the regulation of genesoperates. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts